论文部分内容阅读
AMED(日本版NIH)及其制药企业,政策制定与战略规划需要循证。为此,本研究尝试基于新的指标体系进行制药行业的现状俯瞰与未来预测。本篇通过对不同事业主体、疾病的分析,尝试俯瞰以美国政府机构为中心的药物开发有关的基金动向。
AMED (Japan Edition NIH) and its pharmaceutical companies need evidence-based policy development and strategic planning. To this end, this study attempts to review the status quo and future of the pharmaceutical industry based on the new index system. This article attempts to overlook the trends of funds related to drug development centered on U.S. government agencies through analysis of different business entities and diseases.